BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
Go back to BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.50 | 52 Week High | $108.96 | |||
| Open | $56.50 | 52 Week Low | $62.12 | |||
| Day High | $56.50 | P/E | N/A | |||
| Day Low | $56.50 | EPS | $-1.27 | |||
| Volume | 99 | |||||
